Evidence map›Paper›PMID 30123328›Full record

ArticleJournal of drug delivery science and technology2018

Nebulization of Single-Chain Tissue-Type and Single-Chain Urokinase Plasminogen Activator for Treatment of Inhalational Smoke-Induced Acute Lung Injury.

Soraya Hengsawas Surasarang, Sawittree Sahakijpijarn, Galina Florova, Andrey A Komissarov, Christina L Nelson, Enkhbaatar Perenlei, Satoshi Fukuda, Marla R Wolfson, Thomas H Shaffer, Steven Idell and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of drug delivery science and technology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Soraya Hengsawas SurasarangThe University of Texas at Austin, College of Pharmacy, Division of Molecular Pharmaceutics and Drug Delivery, Austin, TX, USA.
Sawittree SahakijpijarnThe University of Texas at Austin, College of Pharmacy, Division of Molecular Pharmaceutics and Drug Delivery, Austin, TX, USA.
Galina FlorovaThe University of Texas Health Science Center at Tyler, School of Medical Biological Sciences, Tyler, TX, USA.
Andrey A KomissarovThe University of Texas Health Science Center at Tyler, School of Medical Biological Sciences, Tyler, TX, USA.
Christina L NelsonThe University of Texas Medical Branch, Translational Intensive Care Unit, Galveston, TX, USA.
Enkhbaatar PerenleiThe University of Texas Medical Branch, Translational Intensive Care Unit, Galveston, TX, USA.
Satoshi FukudaThe University of Texas Medical Branch, Translational Intensive Care Unit, Galveston, TX, USA.
Marla R WolfsonLewis Katz School of Medicine at Temple University, Departments of Physiology, Thoracic Medicine and Surgery, Pediatrics, Philadelphia, PA, USA.
Thomas H ShafferLewis Katz School of Medicine at Temple University, Departments of Physiology, Thoracic Medicine and Surgery, Pediatrics, Philadelphia, PA, USA.
Steven IdellThe University of Texas Health Science Center at Tyler, School of Medical Biological Sciences, Tyler, TX, USA.
Robert O WilliamsThe University of Texas at Austin, College of Pharmacy, Division of Molecular Pharmaceutics and Drug Delivery, Austin, TX, USA.
Austin College · USThe University of Texas Health Science Center at Tyler · USThe University of Texas Medical Branch at Galveston · USTemple University · USThomas Jefferson University · US

Funding

Airway Delivery of Fibrinolytic Therapy for ISALIR01HL118401 · NHLBI · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI ENKHBAATAR, PERENLEI, IDELL, STEVEN · 2014 to 2017
$3.0M
NHLBI NIH HHS R01 HL118401
6 · The paper itself

Abstract

Single-chain tissue-type plasminogen activator (sctPA) and single-chain urokinase plasminogen activator (scuPA) have attracted interest as enzymes for the treatment of inhalational smoke-induced acute lung injury (ISALI). In this study, the pulmonary delivery of commercial human sctPA and lyophilized scuPA and their reconstituted solution forms were demonstrated using vibrating mesh nebulizers (Aeroneb® Pro (active) and EZ Breathe® (passive)). Both the Aeroneb® Pro and EZ Breathe® vibrating mesh nebulizers produced atomized droplets of protein solution of similar size of less than about 5 μm, which is appropriate for pulmonary delivery. Enzymatic activities of scuPA and of sctPA were determined after nebulization and both remained stable (88.0% and 93.9%). Additionally, the enzymatic activities of sctPA and tcuPA were not significantly affected by excipients, lyophilization or reconstitution conditions. The results of these studies support further development of inhaled formulations of fibrinolysins for delivery to the lungs following smoke-induced acute pulmonary injury.

Indexed as

inhalational smoke-induced acute lung injurylyophilizationnebulizationpulmonary deliverySingle-chain tissue-type plasminogen activatorsingle-chain urokinase plasminogen activatorvibrating mesh nebulizers

Identifiers

PMID30123328
PMCPMC6095669
OpenAlexW2800091386

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.